spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Namenda 

 HSMN NewsFeed - 21 Feb 2018
Amneal Introduces Memantine Hydrochloride Extended-Release Capsules, Generic for Namenda XR(R)
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 18 Dec 2017
Neurotrope Appoints Charles S. Ryan as Chief Executive Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 1 May 2017
NEUROTROPE Announces Positive Top-Line Results From Phase 2 Study of Bryostatin-1 for Moderate to Severe Alzheimer's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Sep 2016
Allergan Issues Statement on Namenda XR Patent Litigation Following Announcement of ANDA Approvals
Biopharmaceuticals Generics FDA Litigation
 HSMN NewsFeed - 31 Aug 2016
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 18 May 2015
Actavis Launches NAMZARIC(TM) (memantine hydrochloride extended-release and donepezil hydrochloride), a Fixed-Dose Combination Therapy for the Treatment of Moderate to Severe Alzheimer's Disease
Biopharmaceuticals Neurology Product Launch
 HSMN NewsFeed - 24 Dec 2014
Actavis and Adamas Announce FDA Approval of Namzaric(TM), a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 19 May 2014
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Feb 2014
Forest Laboratories, Inc. Files Lawsuit Against Several Companies for Infringement of NAMENDA XR(R) Patents
Biopharmaceuticals Neurology Generics Litigation
 HSMN NewsFeed - 14 Nov 2012
Forest Laboratories and Adamas Pharmaceuticals Enter into Licensing Agreement for the Development and Commercialization of a Fixed Dosed Combination of Namenda XR(R) and Donepezil for Alzheimer’s Disease
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 10 Nov 2010
Forest Laboratories, Inc. Announces Executive Management Promotions and Retirement of Lawrence Olanoff as President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Aug 2010
Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Jul 2010
Mylan Announces Settlement Agreement for Namenda(R)
Biopharmaceuticals Generics
 HSMN NewsFeed - 21 Jan 2010
Lupin Receives US FDA Tentative Approval for Memantine HCl Tablets
Biopharmaceuticals Generics Neurology FDA
 HSMN NewsFeed - 30 Jul 2008
New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 May 2008
Myriad Genetics Selects Lundbeck as European Partner for Flurizan
Biopharmaceuticals Neurology
 HSMN NewsFeed - 12 May 2008
Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
Biopharmaceuticals
 HSMN NewsFeed - 11 Apr 2008
Endo Announces Executive Appointment
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Mar 2008
Forest Laboratories Announces Resignation of Ivan Gergel, MD
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Feb 2008
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
Biopharmaceuticals
 HSMN NewsFeed - 1 Feb 2008
Neuro-Hitech Reports Cognitive Improvement From Phase Two Clinical Trial of Huperzine A In Alzheimer's Disease Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 Jan 2008
Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
Biopharmaceuticals Litigation
 HSMN NewsFeed - 22 Jan 2008
Novexel and Forest Laboratories Announce License Agreement for NXL 104, a Novel Broad-Spectrum Beta Lactamase Inhibitor
Biopharmaceuticals Licensing
 HSMN NewsFeed - 11 Jan 2008
Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
Biopharmaceuticals Generics
 HSMN NewsFeed - 31 Dec 2007
Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Dec 2007
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 13 Dec 2007
Forest Laboratories Receives Notification of ANDA Filings for Generic Equivalents of Namenda(R)
Biopharmaceuticals Generics
 HSMN NewsFeed - 2 Dec 2007
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Nov 2007
Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
Biopharmaceuticals
 HSMN NewsFeed - 17 Sep 2007
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Sep 2007
Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 4 Sep 2007
Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 21 Aug 2007
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
Biopharmaceuticals
 HSMN NewsFeed - 31 May 2007
Topline Results of Phase III Study in Acute Ischemic Stroke (Dias-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 May 2007
BENICAR HCT(R) Reductions in Seated Systolic Blood Pressure for Stage 2 Patients Compared With Amlodipine + Benazepril
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 21 May 2007
Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 1 May 2007
Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 11 Jan 2007
Forest Laboratories Announces Completion of Acquisition of Cerexa, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Dec 2006
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Dec 2006
Forest Laboratories Announces Acquisition of Cerexa, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Oct 2006
Patient Recruitment to Resume Without Modification of Protocol for Desmoteplase Phase IIB/III Stroke Study DIAS-2
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Oct 2006
U.S. Food and Drug Administration Issues Non-Approvable Letter for Faropenem
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Sep 2006
Forest Laboratories Inc. Announces Appointment of Dr. Lawrence S. Olanoff as President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jul 2006
Forest Announces Federal Court Upholds Lexapro(R) Patent
Biopharmaceuticals Generics Litigation
Return to NewsFeed  

 Additional items found! 39

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 39 additional stories matching:
Namenda
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.